NXPL

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Consolidated gross margin hit a record ~40% in Q2 2026, up from 22% a year ago. Net loss nearly eliminated, with operating loss down 93% year-over-year to $127K. Contracted pharmacy revenue surged 136% year-over-year to $2.2 million. Healthcare gross margin improved to 46% from 20% in the prior year quarter. Both operating segments (healthcare and e-commerce) were profitable in Q2. Cash position strengthened to $11.9 million with no meaningful debt. Record 6 new 340B contracts added in Q2, following a record 5 in Q1. E-commerce revenue up 27% sequentially, with strong demand in government/military sector. Company expects to reach bottom-line profitability starting in Q3 2026. Planned acquisition of a profitable pharmacy near Pensacola to expand footprint. Total net revenues declined year-over-year to $11.9 million from $13.2 million. Retail prescription revenue fell to $5.6 million from $8.2 million due to lower reimbursement rates and payer mix. Operating expenses increased 2% year-over-year, driven by higher professional fees. Cash used in operating activities was $1.5 million in the first half of 2026. The company faces ongoing legal proceedings with no update provided. Contracted business remains concentrated among a limited number of entities, causing margin volatility. Year-over-year revenue comparisons remain unfavorable due to restructuring and reimbursement dynamics. The Pensacola acquisition will absorb transaction and integration costs in Q3. No shares sold under ATM program, but it remains available, indicating potential future dilution. The company's forward-looking profitability expectations are subject to risks and uncertainties. Warning! GuruFocus has detected 5 Warning Signs with NXPL. Is NXPL fairly valued? Test your thesis with our free DCF calculator. Q: Can you comment on additional acquisitions in the pharmacy space? Are you looking beyond Florida? How would you fund future acquisitions, would you have to dilute current shareholders? A: David Phipps, CEO, stated that the company sees many advantages to concentrating its brick-and-mortar focus on Florida due to attractive population demographics and well-established infrastructure. They are actively exploring additional acquisitions in Florida that meet specific requirements, such as markets not saturated by larger chains and profitable operations. He emphasized a conservative approach to funding, noting flexibility to use a combination of restricted shares, earnouts, cash, or bank lines of credit to capture value without simply diluting shareholders. Q: Will AI play a role in the company's operations? If so, how will it affect the company's business? A: David Phipps, CEO, explained that AI is becoming increasingly important to their growth strategy and operating capabilities. It enables them to identify and respond to trends across e-commerce and healthcare businesses more quickly and helps efficiently process and analyze growing volumes of patient data. AI is a core component of Clear Metrics 4, their proprietary healthcare data analytics platform, and they have developed several new internal systems on the e-commerce side that automate tasks and improve efficiency using AI. Q: Does the company have any update on the status of the ongoing lawsuit? A: David Phipps, CEO, stated that there is no update beyond what has already been disclosed in previously filed periodic reports. The Form 10-Q for the second quarter will be filed shortly and will contain a current disclosure on the matter. He noted the lawsuit remains in the hands of counsel and their insurance company, and they remain committed to resolving it as quickly as possible while protecting the long-term interests of shareholders. Q: What is driving the significant improvement in gross margin and the path to profitability? A: Amanda Ferrio, CFO, highlighted that consolidated gross margin improved to a record 40% in Q2 2026, up from 22% in the prior year period, driven by a strategic shift toward higher-margin contracted healthcare services, particularly 340B and medication fulfillment. Healthcare gross margin reached 46%, the strongest quarterly performance in company history. She noted that with improved fundamentals and anticipated contributions from new contracted services, they expect to reach bottom-line profitability beginning in Q3 2026 and sustain it into 2027, though Q3 will absorb transaction and integration costs related to the pharmacy acquisition. Q: How is the contracted pharmacy revenue growth progressing, and what is the outlook for new 340B contracts? A: Bruta Nkuta, VP of Healthcare Operations, reported that contracted pharmacy revenue increased 136% year-over-year to approximately $2.2 million in Q2, driven by medication fulfillment contracts secured in late 2025 and early 2026. They secured six new 340B contracts in Q2, beating the Q1 record of five. These agreements typically require about 90 days to onboard, with revenue from Q1 entities expected to contribute late in Q3 and Q2 entities more fully in Q4. The contracted business now represents approximately 61% of total healthcare gross profit. Q: What is the status of the Pensacola pharmacy acquisition and how does it fit into the growth strategy? A: Bruta Nkuta, VP of Healthcare Operations, confirmed that subsequent to quarter end, they announced an agreement to acquire a profitable pharmacy operation in the Pensacola area of northwest Florida, a market they do not currently serve. The transaction is expected to close by Q4, subject to customary closing conditions, and will be funded from cash on hand. This acquisition provides a licensed physical platform to introduce higher-value services like 340B support and contracted medication fulfillment, a model they intend to apply as they evaluate additional markets. Q: Can you provide more detail on the e-commerce segment performance and its outlook? A: Amanda Ferrio, CFO, noted that e-commerce operations were essentially flat with the prior year period but up 27% sequentially to $4.1 million in Q2, with gross margin improving to 27%. David Phipps, CEO, added that global demand for satellite-based connectivity products remains strong, with sales to customers in 115 countries and record levels of high-margin recurring airtime contract revenue. There is particular strength in the government and military sector in Europe, with over $1.75 million in sales to government sector customers in the first half of 2026. Q: What are the key drivers behind the year-over-year decline in total revenue, and when will comparisons become more favorable? A: Amanda Ferrio, CFO, explained that total net revenues were $11.9 million in Q2 2026, down from $13.2 million in the prior year period, primarily reflecting lower payer reimbursement rates and payer mix in the retail pharmacy business. However, she emphasized that the more important trend is sequential improvement, with revenue up more than 20% from Q1 2026. She stated that looking to Q3 and Q4, in addition to continued sequential improvement, year-over-year comparisons should become more favorable as contracted services growth offsets expected headwinds. Q: How is the company managing operating expenses, and what is the expectation for professional fees? A: Amanda Ferrio, CFO, reported that total operating expenses were $4.8 million in Q2, an increase of about 2% year-over-year, entirely attributable to a $0.5 million increase in professional fees within SG&A. Every other operating expense line declined or remained flat. She noted that excluding the increase in professional fees, the operating expense base declined year-over-year, and they expect the elevated professional fee level to moderate as the year progresses, supporting improved operating leverage. Q: What is the company's cash position and how will it support future growth initiatives? A: Amanda Ferrio, CFO, stated that the company ended Q2 with $11.9 million in cash, an increase of $0.9 million from March 31, with working capital of $14.2 million and no meaningful debt. She noted that cash used in operating activities improved to $1.5 million for the first six months, down from $3.1 million in the prior year period. The company has not sold any shares under the at-the-market program established in May, which remains available for financial flexibility to support growth initiatives, including potential joint ventures or acquisitions. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Growth Momentum Continues Across the Business, Highlighted by Increased Higher-Margin 340B Healthcare Prescription Volumes and Over 27% Sequential Growth in E-Commerce Revenue HALLANDALE BEACH, Fla., Aug. 13, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced significantly improved operating results for the second quarter ended June 30, 2026. "The second quarter of 2026 marked a clear financial inflection point in NextPlat's turnaround as we generated strong sequential revenue growth, expanded consolidated gross margin to a record 40%, and reduced our net loss to $144,000," said David Phipps, Chief Executive Officer and President of NextPlat Corp. "NextPlat's significantly improved financial results reflect a more efficient operating structure and a deliberate shift toward higher-margin 340B contracted pharmacy services. Supported by 11 new contracted entities signed during the first half of 2026 and customer onboarding underway, our focus is now on converting this pipeline into revenue, maintaining margin discipline, and achieving sustainable profitability including selective, strategically aligned acquisitions that can add scale and diversification." Second Quarter 2026 Financial Highlights: Consolidated revenue for the quarter ended June 30, 2026, was approximately $11.9 million, a sequential increase of approximately 21% over first quarter 2026 revenue of $9.9 million reflecting the Company's continued focus on expanding its contracted healthcare business Overall gross margin for the second quarter ended June 30, 2026, reached a record level of approximately 40%, surpassing the previous record of 35% set in the first quarter ended March 31, 2026, and up approximately 18 percentage points from 22% in the prior-year second quarter. Total operating expenses for the quarter ended June 30, 2026 slightly increased to approximately $4.8 million from approximately $4.7 million in the prior year quarter primarily reflecting a $0.5 million increase in professional fees. Excluding a one-time increase in professional fees, overall operating expenses declined approximately 8% due to the Company's ongoing refocusing and streamlining efforts. Management continues to expect that the addition of higher-margin contracted healthcare services revenue supported by the Company's more efficient expense structure will contribute to sustainable positive operating income for the remainder of 2026. Net loss attributable to common stockholders for the quarter ended June 30, 2026 decreased approximately 92% to approximately $0.1 million or ($0.05) per diluted share, compared to a net loss attributable to common stockholders of approximately $1.8 million, or ($0.69) per diluted share for the three months ended June 30, 2025. Excluding the one-time impact of approximately $0.5 million in professional fees, the Company achieved profitability during the second quarter and anticipates generating positive earnings moving forward. The Company ended the quarter with approximately $11.9 million in cash, working capital of approximately $14.2 million, and no material unsecured debt as of June 30, 2026. Organizational Highlights and Recent Business Developments: During the quarter, momentum in the Company's Healthcare Operations segment continued to build as higher-margin 340B contracted pharmacy services prescription volumes grew over 33% year-over-year, driven primarily by enhanced customer service and support. Successful new 340B business development efforts continued to result in the signing of new services contracts, securing five new entities in the first quarter and six in the second quarter, each representing sequential records. Onboarding of these new customers is currently underway. These additions are expected to contribute to increased revenue throughout the third quarter with a more significant contribution expected early in the fourth quarter. After the close of the second quarter, the Company announced the intended acquisition of a profitable pharmacy operation in the Pensacola area of Northwest Florida. Once completed, this strategic acquisition can enhance the Company's PharmcoRx pharmacy operation, diversifying and expanding its reach into an underserved market as a platform supporting the launch of new high-value healthcare services for regional providers and patients. The Company is currently exploring additional selective acquisitions that could significantly increase the scale of its brick-and-mortar business in Florida. E-commerce sales during the second quarter continued to produce strong sequential growth including improved margins, driven largely by increased sales of satellite-based IoT and Push-to-Talk (PTT) hardware and higher-margin airtime services in international markets supporting government and military sector customers. Through the end of the second quarter, government and military sector sales surpassed $1.75 million. During the third quarter of 2026, the Company expects to launch its new nationwide medication fulfillment website, providing consumers across all 50 U.S. states with convenient online access to prescription and over-the-counter healthcare products. The new platform is expected to significantly expand PharmcoRx's reach beyond Florida, establish a scalable national e-commerce sales channel and support future healthcare revenue growth through broader consumer access and new partnership opportunities. Second Quarter 2026 Conference Call Notification NextPlat's Chief Executive Officer and President, David Phipps, its Chief Financial Officer, Amanda Ferrio, and Vice President of Healthcare Operations, Birute Norkute, will host a conference call today, August 13th at 8:30 a.m. Eastern time to discuss the results for the quarter ended June 30, 2026, as well as other recent developments. To access the call, please use the following information: Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1770457&tp_key=6a139162d1 and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar/detail/20260813-q2-2026-results-conference-call. A replay of the conference call will be available after 12:00 p.m. Eastern time through August 27, 2026. The financial information included in this press release should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, to be filed with the Securities and Exchange Commission. About NextPlat Corp NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care. Forward-Looking Statements Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Media and Investor Contact for NextPlat Corp: Michael GlickmanMWGCO, [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-reports-21-sequential-quarterly-revenue-growth-87-reduction-in-quarterly-net-loss-to-144-000-and-record-gross-margin-of-approximately-40-302850329.html

Investor Conference Call Scheduled for Thursday, August 13, 2026 at 8:30 a.m. Eastern HALLANDALE BEACH, Fla., Aug. 3, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it will release its financial results for the second quarter ended June 30, 2026 on August 13, 2026. NextPlat's CEO, President and CEO of Global Operations, David Phipps, its Chief Financial Officer, Amanda Ferrio and Vice President of Healthcare Operations, Birute Norkute will host a conference call on Thursday, August 13th at 8:30 a.m. Eastern to discuss the results for the second quarter ended June 30, 2026, as well as other recent developments. Investors are requested to submit their questions for the Q&A portion of the call prior to August 10, 2026, at [email protected]. To access the call, please use the following information: Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1770457&tp_key=6a139162d1 and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar. A replay of the conference call will be available after 12:00 p.m. Eastern time through August 27, 2026. For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X. About NextPlat Corp NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to provide access to high quality healthcare and pharmacy services supporting patients, providers, institutions, and public-sector organizations and creating online sales channels for the sales of products to domestic and international consumers. Through its subsidiaries, NextPlat provides pharmacy and healthcare data management services and prescription fulfillment services in the United States and operates an e-commerce division offering voice, data, tracking, and IoT products and services worldwide. Forward-Looking Statements Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors including its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Media and Investor Contact for NextPlat Corp:Michael GlickmanMWGCO, [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-to-release-second-quarter-2026-results-on-thursday-august-13-2026-302840653.html

Image source: The Motley Fool. Thursday, May 14, 2026 at 8:30 a.m. ET Chief Executive Officer — David Phipps Chief Financial Officer — Amanda Ferrio President, Healthcare Segment — Birute Norkute Need a quote from a Motley Fool analyst? Email [email protected] Operator Welcome to the NextPlat first quarter 2026 earnings conference call. Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the company's business and any of its products, services, or solutions. The words believe, forecast, project, intend, expect, plan, should, would, and similar expressions in all statements which are not historical facts are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties, and other factors, any of which could cause the company to not achieve some or all of its goals or the company's previously reported actual results, performance, finance, or operating, including those expressed or implied by such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, the SEC. Copies of which may be obtained from the SEC's website at www.sec.gov. The company assumes no and hereby disclaims any obligation to update the forward-looking statements made during this conference call. Joining us on the call today are David Phipps, Amanda Ferrio, and Birute Norkute. I will now turn the meeting over to David Phipps for opening remarks. David Phipps Good morning, welcome to NextPlat's first quarter 2026 results conference call. Thank you for joining us. On today's call, we will discuss our first quarter results and highlight many of the improvements now being delivered in our business because of our turnaround efforts. In addition to discussing the results of the quarter, we will also share with you some insights into what we expect for the remainder of 2026, specifically the progress we are making on achieving our growth and profitability goals. As is customary, I will begin today's call by briefly recapping the results of the first quarter. I will turn the call over to Birute Norkute to discuss that segment in more detail, and then turn the call over to Amanda Ferrio to review our financial results. Following that, I will make closing remarks and then conclude the conference call by responding to questions that were submitted by our shareholders. Let me start by commenting on our Nasdaq listing status. On April 27th, we announced that we regained our compliance with Nasdaq's minimum bid requirement as a result of us completing a required reverse split. As I indicated on our last call, this was not something we wanted to do. It was required to maintain our listing on Nasdaq, which we believed was in the best interest of our shareholders. With that behind us, instead of looking back, we are now 100% focused on delivering on the promise we see of a bright future for our company, as evidenced by our significantly improved Q1 operating results announced today. These improvements are the direct result of our efforts to turn the business around and position it for long-term profitable growth. As you can see, we now have a fundamentally improved business featuring dramatic margin expansion, supported by a leaner operating structure and an expanding domestic and international new business pipeline. With the turnaround largely complete, we are now looking to add scale and expand the scope of our business, in particular in our healthcare operations. This is highlighted by our expansion into all 50 states from our current base in Florida and other developments which we intend to announce shortly. I will discuss these and other critical developments in a minute. Looking at the first quarter, the positive trends established late last year, and as outlined in our previous guidance announcement, have continued. The business is now beginning to deliver tangible financial results. This is especially visible in terms of improved profitability, as reflected by a consolidated gross margin percentage, which is now at record levels. This is largely driven by a dramatic improvement in our healthcare business, which represented about 68% of our revenue in the first quarter. As we previously indicated, our efforts here were focused on new business development, targeting higher margin, 340B covered entities and long-term care facilities, securing medication fulfillment contracts, re-engagement with former clients, and improving customer service. Initiated late last year, these efforts are now delivering sustainable margin improvement and are expected to support revenue growth later this year. This is a major contributor to our ability to achieve operational profitability in the latter half of 2026. As evidenced by our first quarter results, the combination of new higher margin revenue and a greatly streamlined and cost-efficient operating structure means that we have created a clear path to meaningful reductions in operating losses in the second half of the year. At this point, I'd like to now review our business and provide some additional insights, which I believe will be helpful for investors in measuring our progress. In our healthcare segment, we are pleased to report the following improvements in operations during the first quarter. Revenue continues to be down on a year-over-year basis, as expected, our focus on attracting and supporting the needs of contracted 340B entities, long-term care providers, and other healthcare facility operators is delivering bottom-line improvements. Furthermore, momentum in this segment is building, having secured new 340B pharmacy service agreements with five new entities, a single quarter record. These entities are now onboarding a process which usually takes about 90 days to complete before they can start directing prescriptions for us for fulfillment. As such, we believe these new customers will start contributing to our revenue during the third quarter. The contributions for our medication fulfillment contracts continue to surpass expectations as we filled an average of 7,500 prescriptions per month to the contract facilities in Florida. The service fees we recognize from these fulfillments are driving significant bottom-line profit improvement each month. In terms of retail, although we remain focused on expanding our contracted services, over the past few months we have seen some improvement in this segment of our business. As we are now demonstrating, a well-managed retail pharmacy operation combined with strong margin discipline, operational efficiency, and strategic customer relationships can continue to generate attractive margins and meaningful profitability. Birute will comment a bit more on this in just a minute. Finally, as I mentioned earlier, we are now actively expanding the scale and scope of our business, currently through our newly created nationwide partnership. We are now moving quickly to leverage our relationships with current and potential customers and preparing for the launch of a new online e-commerce healthcare website, which will feature an array of popular prescription medications such as GLP-1s and over-the-counter products, including our Florida Sunshine brand premium vitamins and supplements. The new site is expected to go live before the end of the second quarter. Additionally, I can say we're working on other developments here, which we believe will quickly add more scale to our PharmCo operations in the state of Florida, which we hope to announce very soon. In our e-commerce segment, here are the most recent highlights. We continue to see strong global demand for satellite connectivity products during Q1, generating sales from customers in more than 130 countries. Several European government and military orders received during the quarter have helped to build a strong business pipeline for the coming years, supported by the award of multiple multi-year contracts. These orders, together with the recent growth in demand for satellite-enabled IoT products offered by our partners such as Iridium and Globalstar, have driven IoT sales and recurring revenue to record highs. At this point, I would like to now turn the call over to Birute for her updates. Birute Norkute Thank you, David. As David mentioned, during the first quarter, we continued executing on the operational restructuring and strategic repositioning of our healthcare business with a strong focus on improving margin quality, operational efficiency, and long-term scalability. While overall retail prescription volume during the quarter declined compared to the prior year period, we significantly improved the profitability and quality of our pharmacy operations. Gross margin within the pharmacy business improved to an impressive 39% compared to approximately 20% in the prior year period. This improvement was driven by optimization of payer and product mix, stronger gross profit per retail prescription, and increasing contributions from higher margin 340B relationships and contracted medication fulfillment services. Additionally, beginning January first, 2026, the federally implemented Medicare Maximum Fair Price program impacted reimbursement economics on certain Medicare prescriptions. While this government program was not company-specific, the updated reimbursement framework favorably affected margins on certain therapies that historically generated lower profitability under prior pricing structures, contributing to overall improvement in pharmacy gross profit during the quarter. Importantly, these results demonstrate that well-managed pharmacy operations, combined with strong margin discipline, operational efficiency, and strategic customer relationships, can continue to generate attractive margins and meaningful profitability. We believe this operating model supports our long-term expansion strategy, including selective acquisitions in strategic markets where we can expand our geographic footprint, strengthen local relationships, and further support covered entities and healthcare providers. We are also continuing to invest in future growth initiatives across both our 340B and long-term care verticals, including expansion of our sales and account management teams to support additional business development opportunities throughout Florida and other strategic markets. Another important strategic development during the quarter was entering in nationwide fulfillment partnership designed to support our expansion beyond Florida. While the operational rollout and supporting infrastructure are still in development, we believe this relationship creates an important foundation for future national growth. Over time, we expect the platform to support broader prescription access, cash pay opportunities, e-commerce initiatives, and future offerings in high-demand therapeutic categories, including GLP-1 therapies. Overall, we believe the operational improvements implemented over the last several quarters have created a substantially more efficient and scalable healthcare platform, positioning us for sustained margins and growth as additional customers and partnerships come online through 2026. That concludes my remarks. Back to you, David. David Phipps Thank you, Birute. At this point, I'll turn the call over to Amanda to discuss our financial results for the quarter ended March 31st, 2026. Amanda Ferrio Thank you, David. Good morning, everyone. Before I begin, I want to reinforce David's comments regarding the operational and financial progress we are seeing across the company. The initiatives implemented throughout 2025 are translating into measurable improvements in margins, operating efficiency, and overall financial performance. Our focus entering 2026 has been very clear: stabilize the business, improve profitability, reduce operating losses, and position the company for more consistent and scalable earnings. Based on our first quarter results, we believe we are making meaningful progress toward those objectives. For the first quarter of 2026, total net revenues were approximately $10 million, compared to approximately $14 million in the prior year period and approximately $13 million in the fourth quarter of 2025. While year-over-year revenue comparisons continue to reflect the operational restructuring and evolving reimbursement dynamics within our healthcare business, we believe the more important trend is the sequential improvement we are seeing in margins and operating leverage. Within healthcare operations, first quarter revenue was approximately $7 million, compared to approximately $10 million in the fourth quarter of 2025. The composition of healthcare revenue continued to shift toward higher value and more sustainable revenue streams, including 340B contract services and medication fulfillment services. Pharmacy contract revenue increased to approximately $1.9 million during the quarter, compared to approximately $1.6 million in the fourth quarter and approximately $1.4 million in the prior year period. This continued growth in 340B-related and contract pharmacy services supports improved margins and greater revenue visibility. At the same time, while retail prescription revenue trends began to stabilize further during the quarter following the operational changes implemented throughout 2025. While retail prescription revenue remains below prior year levels, profitability improved due to higher gross profit per prescription, reflecting changes in dispensing mix, continued margin discipline, and reimbursement changes associated with the Medicare Maximum Fair Price program. Our e-commerce operations continued to perform steadily and remained an important contributor to the overall business. E-commerce revenue was approximately $3.2 million during the quarter, compared to approximately $3 million in the prior year period. Although revenue moderated sequentially from the seasonally strong fourth quarter, the business continues to benefit from stable demand across satellite communications, recurring airtime services, and global e-commerce channels. We continue to see healthy customer activity in both enterprise and government-related markets, and we believe this segment remains well-positioned to provide consistent cash flow generation and long-term growth opportunities. Turning to profitability, consolidated gross profit for the quarter was approximately $3.4 million, compared to approximately $2.9 million in the prior year period and approximately $2.4 million in the fourth quarter. Gross margin improved significantly to approximately 35% in the first quarter of 2026, compared to approximately 21% in the first quarter of 2025 and approximately 18% in the fourth quarter of 2025. This represents one of the strongest quarterly gross margin performances in the company's history and reflects the benefits of our strategy to improve revenue quality and overall operating efficiency. Operating expenses continue to improve as we maintain disciplined cost controls across the business. Total operating expenses favorably decreased to approximately $4.5 million in the first quarter of 2026, compared to approximately $4.9 million in the prior-year period and $5.3 million in the fourth quarter of 2025. Salaries and wages decreased to approximately $2.4 million, compared to approximately $2.7 million in the prior-year period and approximately $2.8 million in the fourth quarter of 2025. Selling, general, and administrative expenses also remained well-controlled. These improvements reflect the benefits of the cost optimization initiatives and operational restructuring actions implemented throughout 2025. As a result of the combined improvement in gross profit and operating efficiency, operating loss improved substantially. Operating loss for the first quarter of 2026 was approximately $1.1 million, compared to approximately $2.1 million in the prior year period and approximately $2.8 million in the fourth quarter of 2025. From a segment perspective, it is important to note that our healthcare operations generated positive segment operating income during the quarter of approximately $24,000, compared to a segment operating loss of approximately $1.2 million in the fourth quarter of 2025 and approximately $0.9 million in the prior year period. This represents a major milestone in the repositioning of the healthcare business and validates the progress we are making in improving overall operating performance. On the balance sheet, we ended the quarter with approximately $11 million in cash and working capital of approximately $14 million. While cash usage during the quarter reflected ongoing working capital investment and timing related to receivables, we continue to maintain a healthy liquidity position and a conservative balance sheet with no meaningful debt, which we believe provides flexibility to support growth initiatives, strategic opportunities, and continued operational execution. In addition, subsequent to quarter end, we've regained full compliance with Nasdaq's minimum bid price requirement following the completion of our reverse stock split in April. Finally, as disclosed in our filing earlier this week, we established an at-the-market equity program with H.C. Wainwright to provide additional financial flexibility to support potential future growth initiatives, including possible joint ventures or acquisitions. Currently, we do not have any specific plans for the use of this program. Looking ahead, our priorities for the remainder of 2026 remain centered on the following: Continuing to expand contract-based healthcare and fulfillment services, sustaining gross margins and improving operating leverage, maintaining disciplined expense management, supporting growth organically through recurring and contract-based revenue streams while also evaluating strategic opportunities such as possible joint ventures or acquisitions, improving cash flow performance and positioning the company for sustained profitability. While the macro environment and reimbursement landscape remain dynamic, we believe the actions we have taken over the past year have materially strengthened the foundation of the business. Most importantly, we believe the sequential financial improvements we are now seeing, specifically in gross margin expansion, healthcare segment profitability, and reduced operating losses, provides encouraging evidence that the operational and strategic initiatives implemented over the past year are beginning to deliver measurable financial results. We remain focused on disciplined execution, operational efficiency, and driving long-term shareholder value. I encourage you to review our financial statements and disclosures in our quarterly report on Form 10-Q for additional details. That concludes my remarks. Back to you, David. David Phipps Thank you, Amanda. Before we turn to investor questions, I'd like to make some closing remarks and provide some insights into what we see over the remainder of 2026. Looking at where NextPlat is today, our team is pleased with the execution of our turnaround, implementing the majority of our planned initiatives. Based upon our steady sequential operational improvements, it's clear that we have not only stabilized the business, but we have put it on a well-defined growth and profitability path. Although there is always more work to be done, we believe we now have a foundation that can support the large growth opportunities we see ahead of us. We see several milestones ahead of us in 2026. For our healthcare customers, providers, and patients, we intend to continue expanding the reach of our offerings across the U.S. through new online and physical channels. In e-commerce, we intend to continue expanding our reach through launching new online marketplaces with a wider array of connectivity and consumer product offerings for consumers, enterprises, and governments. For our investors, we are committed to delivering improved operating results, top and bottom line, and communicating the progress we are making on creating shareholder value based upon solid fundamentals. In conclusion, 2026 represents the start of an exciting new chapter for NextPlat, and we wish to thank our shareholders for their continued support. At this point, we can now conduct the Q&A portion of today's call. We have again asked investors and shareholders to submit their questions in advance, and we would like to thank all of you who did. Question number one. There remain challenges in the retail pharmacy business. Do you still see opportunities in this segment? The short answer is yes. As Birute indicated, we firmly believe that well-managed retail pharmacy operations, ones that combine high-touch services with strong margin discipline, operational efficiency, and strategic customer relationships, can generate attractive margins and meaningful profitability, as we are now demonstrating in our PharmcoRx operations. This is certainly true in less dense or more rural areas where there isn't a significant presence of larger retail chains, and as such is a large opportunity we are very actively exploring, which can allow us to quickly and profitably expand the scale and scope of our retail business. Question number two. Can you comment on the turnaround? Are you still working on improvements? If so, what are they, or is it largely complete? As you can see from our results, our plan over the last 9 months has been successful, resulting in significant improvements in nearly all of our operational metrics. While this effort is largely complete, we intend to build upon this progress by remaining very focused on prudent expense control and on generating high-quality revenue. We are shifting our focus more towards driving growth in the business and leveraging the strong financial foundation we have now established, including adequate cash and no meaningful debt. That is why we are actively exploring ways to add scale to our business, as I previously indicated, and I expect to have more to report on these efforts shortly. Question number three. Can you comment on why the company filed an ATM agreement when you clearly have cash on the balance sheet and no debt? Now that our turnaround is largely complete, as I previously indicated, and we are turning our attention towards growth, we have seen a number of opportunities to expand our business through joint ventures and M&A. As such, we believe an ATM can provide us with more flexibility in how we pursue these opportunities. As Amanda said earlier, at this point in time, we do not have any immediate plans to access the ATM, and I would add, wouldn't consider it at these current levels. Question number four. Does the company have any update on the status of the ongoing lawsuit? As of today, we do not have any specific update we can provide. We are continuing to work with counsel to resolve the final remaining legal matter as quickly as possible while protecting the long-term interests of our shareholders. The matter remains in the hands of counsel and our insurance company. That was the final question that we received from investors. Thank you all again for submitting them. Please remember that you can submit your questions at our investor relations email, which is [email protected], or with our IR contact listed on our press releases, Michael Glickman at [email protected]. That concludes our earnings conference call. We look forward to continuing to share with you our progress in the weeks and months ahead. Have a nice rest of your day. Operator Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect. David Phipps Thank you. Before you buy stock in NextPlat, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and NextPlat wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,852!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,317,207!* Now, it’s worth noting Stock Advisor’s total average return is 984% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 27, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. NextPlat (NXPL) Q1 2026 Earnings Transcript was originally published by The Motley Fool

This article first appeared on GuruFocus. Total Net Revenues: Approximately $10 million, down from $14 million in the prior-year period. Healthcare Operations Revenue: Approximately $7 million, compared to $10 million in the fourth quarter of 2025. Pharmacy Contract Revenue: Increased to approximately $1.9 million, up from $1.6 million in the fourth quarter and $1.4 million in the prior-year period. E-commerce Revenue: Approximately $3.2 million, compared to $3 million in the prior-year period. Consolidated Gross Profit: Approximately $3.4 million, up from $2.9 million in the prior-year period. Gross Margin: Improved to approximately 35%, compared to 21% in the first quarter of 2025. Total Operating Expenses: Decreased to approximately $4.5 million, down from $4.9 million in the prior-year period. Operating Loss: Improved to approximately $1.1 million, compared to $2.1 million in the prior-year period. Healthcare Segment Operating Income: Positive $24,000, compared to a loss of $1.2 million in the fourth quarter of 2025. Cash and Working Capital: Approximately $11 million in cash and $14 million in working capital. Warning! GuruFocus has detected 3 Warning Signs with NXPL. Is NXPL fairly valued? Test your thesis with our free DCF calculator. Release Date: May 14, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. NextPlat Corp (NASDAQ:NXPL) regained compliance with NASDAQ's minimum bid requirement, maintaining its listing status. The company reported significant margin expansion and improved Q1 operating results due to turnaround efforts. Healthcare operations showed a dramatic improvement, with gross margins increasing to 39% from 20% in the prior year. The company secured new 340B pharmacy service agreements with five new entities, a single-quarter record. E-commerce operations continued to perform well, with strong global demand for satellite connectivity products and record IoT sales. Total net revenues for Q1 2026 were approximately $10 million, down from $14 million in the prior-year period. Healthcare revenue decreased to approximately $7 million from $10 million in the fourth quarter of 2025. Retail prescription volume declined compared to the prior-year period, despite improved profitability. The company is still working on resolving an ongoing lawsuit, with no specific updates available. An at-the-market equity program was established, indicating potential future dilution, although there are no immediate plans to access it. Q: There remain challenges in the retail pharmacy business. Do you still see opportunities in this segment? A: David Phipps, CEO: Yes, we believe that well-managed retail pharmacy operations, which combine high-touch services with strong margin discipline, operational efficiency, and strategic customer relationships, can generate attractive margins and meaningful profitability. This is especially true in less dense or rural areas where larger retail chains are not significantly present, presenting a large opportunity for expansion. Q: Can you comment on the turnaround? Are you still working on improvements? If so, what are they? Or is it largely complete? A: David Phipps, CEO: Our turnaround plan over the last nine months has been successful, resulting in significant improvements in nearly all operational metrics. While the effort is largely complete, we remain focused on prudent expense control and generating high-quality revenue. We are now shifting our focus towards driving growth and leveraging our strong financial foundation. Q: Can you comment on why the company filed an ATM agreement when you clearly have cash on the balance sheet and no debt? A: David Phipps, CEO: With our turnaround largely complete, we are exploring opportunities to expand through joint ventures and M&A. An ATM provides flexibility in pursuing these opportunities. Currently, we have no immediate plans to access the ATM and would not consider it at current levels. Q: Does the company have any update on the status of the ongoing lawsuit? A: David Phipps, CEO: We do not have a specific update at this time. We are working with counsel to resolve the remaining legal matter as quickly as possible while protecting shareholder interests. The matter is in the hands of our counsel and insurance company. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Turnaround Efforts Deliver 9% Reductions in Sequential Quarterly Expenses Creating Efficient Foundation for Expected Positive Income from Operations in Latter Half of 2026 HALLANDALE BEACH, Fla., May 14, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced improved operating results for its first quarter ended March 31, 2026 as it continues to execute against its ongoing turnaround efforts. "We are pleased with the significant progress we have made in successfully refocusing our operations to deliver improved results as demonstrated in the first quarter. These results reflect the continuation of the positive trends established late in 2025 as we executed on our plans to improve the fundamentals of the business and create a sustainable foundation for growth throughout 2026," said David Phipps, Chief Executive Officer and President of NextPlat Corp. "Supported by a dramatically more efficient and effective cost structure, enhanced business development capabilities and a renewed commitment to customer service, we believe we are now positioned to capitalize on multiple opportunities ahead of us to drive more profitable growth in the months ahead and to deliver value to all of our stakeholders." First Quarter 2026 Financial Highlights: Consolidated revenue for the quarter ended March 31, 2026, was approximately $9.9 million, compared to approximately $13.9 million for the prior year period, an overall decrease of 29% which reflects the expected decline in overall healthcare revenue. First quarter 2026 Healthcare Operations pharmacy prescription revenue decreased to approximately $4.8 million from approximately $9.5 million in the prior year period. The year-over-year decrease was primarily driven by lower reimbursement rates of approximately $3.0 million and the anticipated contraction in prescription volume of approximately $1.7 million, reflecting the changes in payer reimbursement rates and overall payer mix. First quarter 2026 Healthcare Operations pharmacy contract revenue increased to approximately $1.9 million from approximately $1.4 million in the prior year period. This increase was attributable to the medication fulfillment contract services secured late in 2025. Sequentially, first quarter 2026 pharmacy contract revenue increased approximately 19% versus the fourth quarter of 2025 driven by continued business development activity and customer service enhancements focused on contract customers. These results demonstrate that well-managed pharmacy operations, combined with strong margin discipline, operational efficiency, and strategic customer relationships can continue to generate attractive profitability despite ongoing reimbursement pressures across the industry. First quarter 2026 e-Commerce revenues increased to approximately $3.2 million from approximately $3.0 million in the prior year period primarily due to an increase in airtime sales of approximately $0.2 million. Through the first five months of 2026, the Company continued to see strong global demand for satellite-based connectivity and IoT products highlighted by new and expanded orders in support of international government and military customers for Iridium and Globalstar devices. Overall gross margin for the quarter ended March 31, 2026, improved dramatically to approximately 35%, a quarterly record, up from the prior year quarter of approximately 21%, and up sequentially from approximately 20% recorded for the full year ended December 31, 2025. Gross margin for Healthcare Operations nearly doubled to approximately 39% in the first quarter of 2026 compared to approximately 20% in the first quarter of 2025, and sequentially up from approximately 18% in the fourth quarter of 2025. The dramatic increase in gross margin was attributable to the addition of new contracted medication fulfillment services as well as the improved drug costing as a result of the Medicare Maximum Fair Price program which began in January 2026. As a result of increasing levels of higher margin 340B and medication fulfillment contracted services revenue, this operating segment's gross margin is anticipated to remain elevated throughout the remainder of 2026. Gross margin for e-Commerce Operations increased slightly in the first quarter of 2026 to approximately 25% from 24% when compared to the first quarter of 2025. Total operating expenses for the quarter ended March 31, 2026, decreased to approximately $4.5 million from approximately $4.9 million in the prior year quarter, a reduction of approximately $0.4 million, or 9%. Overall operating expenses declined significantly due to the Company's ongoing refocusing and streamlining efforts highlighted by decreases in salaries and wages resulting from reductions in total headcount and executive compensation as well as decreases in professional fees. Management expects that the addition of higher margin contracted healthcare services revenue combined with reduced levels of operating expenses throughout 2026 will enable the Company to achieve positive operating income in the latter half of 2026. Net loss attributable to common stockholders for the quarter ended March 31, 2026 decreased 42% to approximately $1.1 million, or ($0.42) per diluted share, compared to a net loss attributable to common stockholders of approximately $1.9 million, or ($0.75) per diluted share for the three months ended March 31, 2025. Based upon additional higher-margin contracted healthcare services revenue combined with prudent expense controls, the Company anticipates significant reduction of losses by the fourth quarter of 2026. The Company ended the quarter with approximately $11.0 million in cash, working capital of approximately $14.2 million, and zero unsecured debt as of March 31, 2026. The Company expects that a portion of the outstanding receivables contributing to the timing-related decreases in cash collections during the first quarter of 2026 will be collected during the second quarter of 2026; however, the timing of such collections may vary. Organizational Highlights and Recent Business Developments: In March 2026, NextPlat announced its latest healthcare growth initiative through a nationwide fulfillment partnership which is expected to significantly expand the Company's addressable market beyond Florida where the Company's healthcare operations segment generated nearly $40 million in annual revenue last year. In addition to supporting NextPlat's current healthcare clients with multi-state operations, the new nationwide fulfillment capabilities will support the launch of the Company's new healthcare e-commerce site. The new site will feature an array of popular prescription medications and Over-the-Counter (OTC) products including its Florida Sunshine brand of premium vitamins and supplements and is expected to go live before the end of the second quarter of 2026. The Company continues to invest in its Healthcare Operations business development and customer service improvement efforts to drive growth initiatives across both pharmacy contracted services and long-term care customers. At the end of the first quarter, the Company contracted five new 340B entities, a single quarter record. These new 340B entities are expected to commence activities in July 2026. In the first quarter, the Company's e-commerce sales and distribution platforms for satellite connectivity and communications continued to see strong demand for products from leading providers including Globalstar and Iridium, with significant new orders received from European government and military customers. This demand was highlighted by the Company's Global Telesat Communications Ltd (GTC) subsidiary being awarded a contract from a U.K. government prime supplier for satellite-enabled Internet of Things (IoT) hardware in support of a NATO military customer valued at approximately $820,000. By the end of the first quarter of 2026, GTC generated a government and military sales pipeline valued at over $1.2 million with significant new sales secured in April and May expected to contribute to additional pipeline growth in the second quarter of 2026. First Quarter 2026 Conference Call Notification NextPlat's Chief Executive Officer and President, David Phipps, its Chief Financial Officer, Amanda Ferrio, and Vice President of Healthcare Operations, Birute Norkute, will host a conference call today, May 14th at 8:30 a.m. Eastern time to discuss the results for the quarter ended March 31, 2026, as well as other recent developments. To access the call, please use the following information: Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay at https://app.webinar.net/aK21yzvyep9 and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar/detail/20260514-q1-2026-results-conference-call. A replay of the conference call will be available after 12:00 p.m. Eastern time through May 21, 2026. The financial information included in this press release should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, to be filed with the Securities and Exchange Commission. About NextPlat Corp NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care. Forward-Looking Statements Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Media and Investor Contact for NextPlat Corp: Michael Glickman MWGCO, Inc. 917-397-2272 [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-reports-9-9-million-in-revenue-for-q1-2026-with-record-quarterly-consolidated-gross-margins-of-35-302771749.html

Investor Conference Call Scheduled for Thursday, May 14, 2026 at 8:30 a.m. Eastern HALLANDALE BEACH, Fla., May 7, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it will release its financial results for the first quarter ended March 31, 2026 on May 14, 2026. NextPlat's CEO, President and CEO of Global Operations, David Phipps, its Chief Financial Officer, Amanda Ferrio and Vice President of Healthcare Operations, Birute Norkute will host a conference call on Thursday, May 14th at 8:30 a.m. Eastern to discuss the results for the first quarter ended March 31, 2026, as well as other recent developments. Investors are requested to submit their questions for the Q&A portion of the call prior to May 12, 2026, at [email protected]. To access the call, please use the following information: Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay at https://app.webinar.net/aK21yzvyep9 and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar. A replay of the conference call will be available after 12:00 p.m. Eastern time through May 21, 2026. For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X. About NextPlat Corp NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to provide access to high quality healthcare and pharmacy services and assist businesses in selling their goods online, domestically, and internationally, allowing them to optimize their e-commerce presence and revenue. Through its subsidiaries, NextPlat provides pharmacy and healthcare data management services and prescription fulfilment services in the United States and operates an e-commerce division offering voice, data, tracking, and IoT products and services worldwide. Forward-Looking Statements Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors including its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Media and Investor Contact for NextPlat Corp: Michael Glickman MWGCO, Inc. 917-397-2272 [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-to-release-first-quarter-2026-results-on-thursday-may-14-2026-302765037.html

This article first appeared on GuruFocus. Total Revenue: Approximately $54 million for the year ended December 31, 2025, an 18% decline from 2024. Healthcare Operations Revenue: Approximately $40 million in 2025, down from $52 million in 2024. 340B Contract Revenue: 94% increase in the fourth quarter of 2025 compared to the third quarter. E-commerce Revenue: Approximately $15 million, a 6% increase year-over-year. Gross Margin: Approximately 20% for the full year 2025, down from 26% in 2024. Operating Expenses: Decreased by approximately 25% to $20 million, excluding a non-recurring impairment charge from the prior year. Cash Position: Nearly $14 million in cash with no meaningful debt. Cost Reductions: Over $2 million in annualized overhead, staff, and operational cost reductions. Warning! GuruFocus has detected 3 Warning Signs with NXPL. Is NXPL fairly valued? Test your thesis with our free DCF calculator. Release Date: March 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. NextPlat Corp (NASDAQ:NXPL) has successfully reduced its operating expenses by approximately 25%, leading to over $2 million in annualized cost reductions. The company is expanding its healthcare business nationwide, moving beyond Florida to support customers in all 50 states through a partnership with Health Warehouse. NextPlat Corp (NASDAQ:NXPL) reported a 94% increase in 340B contract revenue in the fourth quarter of 2025, indicating strong growth in this segment. The e-commerce segment continues to grow, with a 6% year-over-year increase in revenue driven by demand for satellite connectivity and Internet of Things products. The company maintains a strong balance sheet with nearly $14 million in cash and no meaningful debt, providing flexibility for future investments and growth opportunities. NextPlat Corp (NASDAQ:NXPL) experienced an 18% decline in total revenue for the year ended December 31, 2025, primarily due to lower contributions from its healthcare operations segment. The reverse stock split was necessary to maintain the company's Nasdaq listing, which may have negative perceptions among investors. The company is facing ongoing legal matters, which could result in additional costs or settlements. Despite improvements, the consolidated gross margin for the full year decreased to approximately 20% from 26% in 2024. The transition to higher-margin contracted services may impact top-line revenue and prescription volumes in the first half of 2026. Q: Do you believe that the reverse split was necessary? Couldn't the company buy back stock to achieve the $1 minimum bid requirement? A: David Phipps, CEO: The buyback program expired in December, and we have been in a blackout period since then, so repurchasing shares hasn't been an option. The buyback program was designed to support the stock price, not drive it up, due to restrictions by the SEC and NASDAQ. Maintaining our NASDAQ listing is crucial for our growth plans, and given the market environment, the reverse split was the most viable option. Q: What are the current plans for the buyback? A: David Phipps, CEO: Reinstating the buyback program is under consideration, and we will announce any details when appropriate. Q: Can you comment on the status of the ongoing lawsuits, and does the accrual mean a settlement is pending? A: David Phipps, CEO: We are working with counsel to resolve the final legal matter while protecting shareholder interests. The paths include proceeding to trial or reaching a settlement, depending on counsel and insurance company opinions. A non-cash contingency charge was taken for potential future litigation costs. Q: How is the company planning to leverage its partnership with Health Warehouse? A: David Phipps, CEO: The partnership with Health Warehouse allows us to expand our healthcare offerings nationally beyond Florida, supporting multi-state contracted customers and creating new revenue streams, including e-commerce and online healthcare offerings. Q: What are the expectations for the healthcare segment's growth in 2026? A: Birute Norkute, VP of Healthcare Operations: We expect continued growth in 340B contract revenue and fulfillment services, with gradual improvement in prescription volumes and a favorable impact on margin profile over time. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Investor Conference Call Scheduled for Tuesday, March 31, 2026 at 8:30 a.m. Eastern HALLANDALE BEACH, Fla., March 25, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it will release its financial results for the full year ended December 31, 2025 on March 31, 2026. NextPlat's CEO, President and CEO of Global Operations, David Phipps, its Chief Financial Officer, Amanda Ferrio and Vice President of Healthcare Operations, Birute Norkute will host a conference call on Tuesday, March 31st at 8:30 a.m. Eastern to discuss the results for the full year ended December 31, 2025, as well as other recent developments. Investors are requested to submit their questions for the Q&A portion of the call prior to March 27, 2026, at [email protected]. To access the call, please use the following information: Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay at https://app.webinar.net/wbRV9ab8NLa and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar. A replay of the conference call will be available after 12:00 p.m. Eastern time through April 7, 2026. For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X. About NextPlat Corp NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care. Forward-Looking Statements Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Media and Investor Contact for NextPlat Corp: Michael Glickman MWGCO, Inc. 917-397-2272 [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-to-release-full-year-2025-results-on-tuesday-march-31-2026-302724731.html